Complement factor H Y402H gene polymorphism and coronary heart disease susceptibility: a meta-analysis
Hai-Feng Zhang1, Jing-Feng Wang, Yan Wang
1Department of Cardiology, The Second Affiliated Hospital, Sun Yat-sen University, 510120 Guangzhou, China.
Molecular Biology Reports
|February 4, 2010
Summary
This meta-analysis found no significant association between the complement factor H (CFH) T1277C gene variant and coronary heart disease (CHD) risk in the general population. Further research is needed to explore potential associations in specific subgroups.
Area of Science:
- Genetics
- Cardiovascular Disease Epidemiology
Background:
- Conflicting reports exist regarding the association between the complement factor H (CFH) Y402H (T1277C) gene polymorphism and coronary heart disease (CHD).
- Understanding genetic predispositions is crucial for CHD risk assessment.
Purpose of the Study:
- To perform a comprehensive meta-analysis evaluating the association between the CFH T1277C polymorphism and CHD risk.
- To synthesize existing evidence and clarify the role of this genetic variant in CHD development.
Main Methods:
- Systematic electronic and manual searches were conducted to identify all relevant studies.
- Meta-analyses were performed using codominant, dominant, and recessive genetic models.
- Publication bias was assessed to ensure the robustness of the findings.
Main Results:
- Ten studies with 11 cohorts and 29,764 participants were included in the overall analysis.
- No statistically significant association was found between the CFH T1277C polymorphism and CHD risk across various models.
- Subgroup analyses, including for Caucasians, also revealed no significant association, though two studies reported positive findings in specific populations.
Conclusions:
- Current evidence does not support a general association between the CFH T1277C polymorphism and CHD risk.
- Potential associations may exist in specific populations and could be influenced by factors like age of onset, risk factor status, and genetic background.
- Further research focusing on diverse populations and these influencing factors is warranted.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...